Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: LIPITOR

« Back to Dashboard
Lipitor is a drug marketed by Pfizer and is included in one NDA. It is available from seventeen suppliers. There are two patents protecting this drug.

The generic ingredient in LIPITOR is atorvastatin calcium. There are fifty-nine drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the atorvastatin calcium profile page.

Summary for Tradename: LIPITOR

Patents:2
Applicants:1
NDAs:1
Suppliers: see list17

Pharmacology for Tradename: LIPITOR

Clinical Trials for: LIPITOR

CKD-391 DDI : Atorvastatin and Ezetimibe in Healthy Volunteers
Status: Completed Condition: Healthy

High Dose and Low Dose of Atorvastatin in Patients With Unstable Angina and NSTEMI (Non ST Elevation MI)
Status: Completed Condition: Cardiovascular Disease

A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)
Status: Completed Condition: Hyperlipidemia

Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia
Status: Completed Condition: Hypertriglyceridemia

Atorvastatin for HAART Suboptimal Responders
Status: Completed Condition: Acquired Immune Deficiency Syndrome Virus

Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease
Status: Enrolling by invitation Condition: Sickle Cell Disease; Sickle Cell Nephropathy

Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus
Status: Terminated Condition: Avascular Necrosis

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin
Status: Completed Condition: Dyslipidaemias

Bioequivalence Study of Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Under Fed Conditions
Status: Completed Condition: Healthy

The Effect of Atorvastatin and Pioglitazone on Carotid Atherosclerosis With the Use of Positron Emission Tomography-computed Tomography (PET-CT)
Status: Completed Condition: Atherosclerosis; Coronary Artery Disease

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer
LIPITOR
atorvastatin calcium
TABLET;ORAL020702-001Dec 17, 1996RXNo5,969,156*PED<disabled>Y<disabled>
Pfizer
LIPITOR
atorvastatin calcium
TABLET;ORAL020702-004Apr 7, 2000RXYes5,969,156*PED<disabled>Y<disabled>
Pfizer
LIPITOR
atorvastatin calcium
TABLET;ORAL020702-002Dec 17, 1996RXNo5,686,104*PED<disabled>Y<disabled>
Pfizer
LIPITOR
atorvastatin calcium
TABLET;ORAL020702-004Apr 7, 2000RXYes5,686,104*PED<disabled>Y<disabled>
Pfizer
LIPITOR
atorvastatin calcium
TABLET;ORAL020702-001Dec 17, 1996RXNo5,686,104*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: LIPITOR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,126,971 Stable oral CI-981 formulation and process for preparing same<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc